Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00 at BMO Capital Markets

Replimune Group (NASDAQ:REPL) had its price objective raised by BMO Capital Markets from $14.00 to $18.00 in a research report released on Friday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

REPL has been the topic of several other reports. Roth Mkm started coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target on the stock. JPMorgan Chase & Co. lifted their price target on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Replimune Group in a research note on Friday. Finally, Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Replimune Group currently has an average rating of “Buy” and a consensus price target of $17.00.

Replimune Group Stock Down 11.2 %

REPL opened at $13.26 on Friday. The firm has a market cap of $907.25 million, a P/E ratio of -4.35 and a beta of 1.19. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The business has a 50 day moving average price of $11.59 and a 200 day moving average price of $9.76. Replimune Group has a twelve month low of $4.92 and a twelve month high of $17.00.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. Research analysts forecast that Replimune Group will post -3.02 EPS for the current year.

Insider Buying and Selling

In related news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 8.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Replimune Group

Several large investors have recently modified their holdings of the stock. Millennium Management LLC boosted its stake in Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after buying an additional 2,656,173 shares in the last quarter. Braidwell LP lifted its holdings in shares of Replimune Group by 203.0% during the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock valued at $33,656,000 after acquiring an additional 2,057,460 shares during the period. State Street Corp boosted its stake in shares of Replimune Group by 102.1% in the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after purchasing an additional 1,182,181 shares in the last quarter. Baker BROS. Advisors LP grew its holdings in shares of Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after purchasing an additional 1,000,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Replimune Group by 12.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after purchasing an additional 699,679 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.